engineered IL-18 therapy (Alkermes)

N/A

Report date: 2025/03/20 15:16:19

Base Information

Drug Nameengineered IL-18 therapy (Alkermes)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionInterleukin 18 stimulants
TargetsInterleukin 18
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesMural Oncology Inc
Inactive CompaniesAlkermes Plc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A